Adoptive T-cell transfer in cancer immunotherapy

Immunology and Cell Biology

Volumn 84, Issue 3, 2006, Pages 281-289

  Tey, Siok Keen ^a   Bollard, Catherine M ^a   Heslop, Helen E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Adoptive immunotherapy; Bone marrow transplantation; Gene therapy; Neoplasm; T lymphocyte

Indexed keywords

BAGE ANTIGEN; BCR ABL PROTEIN; CANCER TESTIS ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAGE ANTIGEN; GENE PRODUCT; GLYCOPROTEIN GP 100; HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; MELANOMA ANTIGEN 1; MYELOBLASTIN; NY ESO 1 ANTIGEN; SSX 1 ANTIGEN; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RELAPSE; CELL FUNCTION; DNA MODIFICATION; EPSTEIN BARR VIRUS; GENE TARGETING; HOST CELL; HUMAN; IMMUNOMODULATION; LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR SUPPRESSOR GENE; VACCINATION;

ADOPTIVE TRANSFER; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES;

HUMAN HERPESVIRUS 4;

EID: 33646094216     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2006.01441.x     Document Type: Review

References (86)

1. Drobyski W Keever C Roth M et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993 82 2310 18.
2. Kolb H Mittermuller J Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990 76 2462 5.
3. Riddell SR Watanabe KS Goodrich JM Li CR Agha ME Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992 257 238 41.
4. Rooney CM Smith CA Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995 345 9 13.
5. Heslop HE Ng CY Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 1996 2 551 5.
6. Rooney CM Smith CA Ng CYC et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998 92 1549 55.
7. Scanlan MJ Gure AO Jungbluth AA Old LJ Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 2002 188 22 32.
8. Zendman AJ Ruiter DJ Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J. Cell. Physiol. 2003 194 272 88.
9. Molldrem JJ Lee PP Wang C et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 2000 6 1018 23.
10. Gao L Bellantuono I Elsasser A et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000 95 2198 203.
11. Dudley ME Wunderlich JR Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002 298 850 54.
12. Yee C Thompson JA Roche P et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 2000 192 1637 44.
13. ten Bosch GJ Toornvliet AC Friede T Melief CJ Leeksma OC. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 1995 9 1344 8.
14. Yotnda P Firat H Garcia-Pons F et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 1998 101 2290 96.
15. Straathof KC Bollard CM Popat U et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus - specific T lymphocytes. Blood 2005 105 1898 904.
16. Marijt WAE Heemskerk MHM Kloosterboer FM et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl Acad. Sci. USA 2003 100 2742 7.
17. Weiden PL Flournoy N Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 1979 300 1068 73.
18. Horowitz M Gale R Sondel P et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990 75 555 62.
19. Papadopoulos EB Ladanyi M Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 1994 330 1185 91.
20. Childs R Chernoff A Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 2000 343 750 58.
21. Lundqvist A Childs R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J. Immunother. 2005 28 281 8.
22. Baron F Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Mol. Ther. 2006 13 26 41.
23. Kolb H-J Schmid C Barrett AJ Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004 103 767 76.
24. Kolb H Schattenberg A Goldman J et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia (see comments). Blood 1995 86 2041 50.
25. Suchin EJ Langmuir PB Palmer E Sayegh MH Wells AD Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 2001 166 973 81.
26. Guglielmi C Arcese W Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002 100 397 405.
27. Amrolia PJ Mucioli-Casadei G Huls H et al. Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation. Cytotherapy 2005 7 116 25.
28. Andre-Schmutz I Le Deist F Hacein-Bey-Abina S et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002 360 130 37.
29. Davies JK Koh MB Lowdell MW. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biol. Blood Marrow Transplant. 2004 10 259 68.
30. Le NT Chen BJ Chao NJ. Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting. Cytotherapy 2005 7 126 33.
31. Solomon SR Mielke S Savani BN et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005 106 1123 9.
32. Montagna D Yvon E Calcaterra V et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 1999 93 3550 57.
33. Mavroudis DA Dermime S Molldrem J et al. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br. J. Haematol. 1998 101 565 70.
34. Amrolia PJ Muccioli-Casadei G Yvon E et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003 102 2292 9.
35. Takayama T Sekine T Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000 356 802 7.
36. Porrata LF Inwards DJ Micallef IN Ansell SM Geyer SM Markovic SN. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br. J. Haematol. 2002 117 629 33.
37. Porrata LF Gertz MA Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001 98 579 85.
38. Laport GG Levine BL Stadtmauer EA et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+ selected hematopoietic cell transplantation. Blood 2003 102 2004 13.
39. Rapoport AP Stadtmauer EA Aqui N et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature Medicine 2005 11 1230 37.
40. Leemhuis T Wells S Scheffold C Edinger M Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. 2005 11 181 7.
41. Bonini C Ferrari G Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997 276 1719 24.
42. Sauce D Bodinier M Garin M et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 2002 99 1165 73.
43. Riddell SR Elliott M Lewinsohn DA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 1996 2 216 23.
44. Garin MI Garrett E Tiberghien P et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 2001 97 122 9.
45. Marktel S Magnani Z Ciceri F et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003 101 1290 98.
46. Bondanza A Valtolina V Magnani Z et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 2005 107 2005 2009.
47. Thomis DC Marktel S Bonini C et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001 97 1249 57.
48. Straathof KC Pule MA Yotnda P et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005 105 4247 54.
49. Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology 2005 2005 260 66.
50. Gottschalk S Rooney CM Heslop HE. Post-transplant lymphoproliferative disorders. Annu. Rev. Med. 2005 56 29 44.
51. Khanna R Bell S Sherritt M et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl Acad. Sci. USA 1999 96 10391 6.
52. Comoli P Labirio M Basso S et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002 99 2592 8.
53. Haque T Wilkie GM Taylor C et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002 360 436 42.
54. Young LS Rickinson AB. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004 4 757 68.
55. Bollard CM Aguilar L Straathof KC et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J. Exp. Med. 2004 200 1623 33.
56. Gottschalk S Edwards OL Sili U et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003 101 1905 12.
57. Bollard CM Straathof KC Huls MH et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J. Immunother. 2004 27 317 27.
58. Montagna D Maccario R Locatelli F et al. Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood 2001 98 3359 66.
59. Falkenburg JHF Wafelman AR Joosten P et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999 94 1201 8.
60. Meidenbauer N Marienhagen J Laumer M et al. Survival and tumor localization of adoptively transferred melan-A-specific T cells in melanoma patients. J. Immunol. 2003 170 2161 9.
61. Vignard V Lemercier B Lim A et al. Adoptive transfer of tumor-reactive melan-A-specific CTL clones in melanoma patients Is followed by increased frequencies of additional melan-A-specific T cells. J. Immunol. 2005 175 4797 805.
62. Dudley ME Rosenberg SA. Adoptive cell transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 2003 3 666 75.
63. Rosenberg SA Yannelli JR Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994 86 1159 66.
64. Dotti G Heslop HE. Current status of genetic modification of T cells for cancer treatment. Cytotherapy 2005 7 262 72.
65. Sadelain M Riviere I Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 2003 3 35 45.
66. Clay TM Custer MC Sachs J Hwu P Rosenberg SA Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 1999 163 507 13.
67. Zhao Y Zheng Z Robbins PF Khong HT Rosenberg SA Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 2005 174 4415 23.
68. Cohen CJ Zheng Z Bray R et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 2005 175 5799 808.
69. Stanislawski T Voss R-H Lotz C et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nature Immunology 2001 2 962 70.
70. Pule MA Straathof KC Dotti G Heslop HE Rooney CM Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 2005 12 933 41.
71. Rossig C Bollard CM Nuchtern JG Rooney CM Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002 99 2009 16.
72. Kershaw MH Westwood JA Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nature Biotechnology 2002 20 1221 7.
73. Wang J Press OW Lindgren CG et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol. Ther. 2004 9 577 86.
74. Yee C Thompson JA Byrd D et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 2002 99 16168 73.
75. Malek TR Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 2004 4 665 74.
76. Liu K Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 2001 167 6356 65.
77. Cheng LE Ohlen C Nelson BH Greenberg PD. Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc. Natl Acad. Sci. USA 2002 99 3001 3006.
78. Rosenberg SA Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl Acad. Sci. USA 2004 101 14639 45.
79. Wrzesinski C Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr. Opin. Immunol. 2005 17 195 201.
80. Robbins PF Dudley ME Wunderlich J et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 2004 173 7125 30.
81. Kershaw MH Wang G Westwood JA et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 2002 13 1971 80.
82. Bollard CM Rossig C Calonge MJ et al. Adapting a transforming growth factor beta -related tumor protection strategy to enhance antitumor immunity. Blood 2002 99 3179 87.
83. Wagner HJ Bollard CM Vigouroux S et al. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004 11 81 91.
84. Gottschalk S Ng CYC Perez M et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001 97 835 43.
85. Khong HT Wang QJ Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J. Immunother. 2004 27 184 90.
86. Mondoro TH Thomas JW Henslee-Downey PJ Peterson CM. NHLBI plans for the promise of cell-based therapies. Cytotherapy 2005 7 317 27.